Smoking and Sickness Absence: a Systematic Review and Meta-analysis
Overview
Occupational Medicine
Authors
Affiliations
Objectives Evidence on the effect of smoking on sickness absence could guide workplace smoking cessation interventions and encourage employers to promote smoking cessation among their employees. This systematic review and meta-analysis aimed to summarize evidence on the association between smoking and sickness absence and determine whether there are differences in this association for study design, methodology, and sample characteristics. Methods We searched for studies that reported on smoking status and sickness absence, used empirical data, were published in a peer-reviewed journal in the last 25 years, and written in English. We conducted pooled analyses in which uni- and multivariate generalized linear regression models were applied. Results After screening 2551 unique records, 46 articles from 43 studies were included, of which 33 studies (with 1 240 723 participants) could be included in the pooled analyses. Smoking was associated with an 31% increase in risk of sickness absence compared to non-smoking (95% confidence interval (CI) 1.24-39). We did not find statistically significant different effect sizes for study location, gender, age, occupational class, study design, assessment of sickness absence, short- versus long-term sickness absence, and adjustment for relevant confounders. Furthermore, smoking was associated with 2.89 more sickness absence days per year compared to non-smoking (95% CI 2.08-3.70). Conclusions We found robust evidence showing that smoking increases both the risk and number of sickness absence days in working populations, regardless of study location, gender, age, and occupational class. Encouraging smoking cessation at the workplace could therefore be beneficial for employers and employees.
Absenteeism Among Healthcare Workers: Job Grade and Other Factors That Matter in Sickness Absence.
Sakr C, Fakih L, Musharrafieh U, Khairallah G, Makki M, Doudakian R Int J Environ Res Public Health. 2025; 22(1).
PMID: 39857580 PMC: 11764580. DOI: 10.3390/ijerph22010127.
Contreras-Osorio F, Cerda-Vega E, Campos-Jara C, Ramirez-Campillo R, Perez-Romero N Healthcare (Basel). 2024; 12(23).
PMID: 39685058 PMC: 11640837. DOI: 10.3390/healthcare12232437.
Knezevic S, Gajic T, Djonovic N, Knezevic S, Vukolic D, Marinkovic T Healthcare (Basel). 2024; 12(22).
PMID: 39595402 PMC: 11593712. DOI: 10.3390/healthcare12222203.
Parkes S, Irizar P, Greenberg N, Wessely S, Fear N, Hotopf M Epidemiol Psychiatr Sci. 2024; 33:e26.
PMID: 38712441 PMC: 11094650. DOI: 10.1017/S2045796024000283.
Mann N, Spencer G, Hutchinson B, Ngongo C, Tarlton D, Webb D Tob Control. 2024; 33(Suppl 1):s17-s26.
PMID: 38697659 PMC: 11103323. DOI: 10.1136/tc-2023-058337.